Opposite effect of two cytomegalovirus DNA polymerase mutations on replicative capacity and polymerase activity

Jacobson M.A. , Stanley H. , Holtzer C. , Margolis T.P. , Cunningham E.T. Natural history and outcome of new AIDS-related cytomegalovirus retinitis diagnosed in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 30: 231–233.

Razonable R.R. , Paya C. V. . Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein–Barr virus infections. Herpes 2003; 10: 60–65.

Sia I.G. , Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000; 13: 83–121.

Biron K.K. , Stanat S.C. , Sorrell J.B. Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1- (hydroxymethyl) ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Natl Acad Sci U S A 1985; 82: 2473–2477.

Cihlar T. , Chen M.S. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol Pharmacol 1996; 50: 1502–1510.

Sullivan V. , Talarico C.L. , Stanat S.C. , Davis M. , Coen D.M. , Biron K.K. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992; 359: 85.

Chrisp P. , Clissold S. P. . Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. Drugs 1991; 41: 104–129.

Chou S. , Marousek G. , Guentzel S. Evolution of mutations conferring multidrug resistance during prophylaxis and therapy for cytomegalovirus disease. J Infect Dis 1997; 176: 786–789.

Erice A. , Gil-Roda C. , Perez J.L. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients. J Infect Dis 1997; 175: 1087–1092.

Limaye A.P. , Corey L. , Koelle D.M. , Davis C.L. , Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000; 356: 645–649.

Limaye A.P. , Raghu G. , Koelle D.M. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy. J Infect Dis 2002; 185: 20–27.

Smith I.L. , Cherrington J.M. , Jiles R.E. High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes. J Infect Dis 1997; 176: 69–77.

Chou S. , Lurain N.S. , Thompson K.D. , Miner R.C. , Drew W.L. Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus. J Infect Dis 2003; 188: 32–39.

Cihlar T. , Fuller M.D. , Mulato A.S. , Cherrington J.M. A point mutation in the human cytomegalovirus DNA polymerase gene selected in vitro by cidofovir confers a slow replication phenotype in cell culture. Virology 1998; 248: 382–393.

Gilbert C. , Boivin G. Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother 2005; 49: 873–883.

Cihlar T. , Fuller M. , Cherrington J. Characterization of drug resistance-associated mutations in the human cytomegalovirus DNA polymerase gene by using recombinant mutant viruses generated from overlapping DNA fragments. J Virol 1998; 72: 5927–5936.

Chou S. , Marousek G.I. , Van Wechel L.C. , Li S. , Weinberg A. Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens. Antimicrob Agents Chemother 2007; 51: 4160–4162.

Tchesnokov E.P. , Gilbert C. , Boivin G. , Gotte M. Role of helix P of the human cytomegalovirus DNA polymerase in resistance and hypersusceptibility to foscarnet. J Virol 2006; 80: 1440–1450.

Landry M.L. , Stanat S. , Biron K. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother 2000; 44: 688–692.

Cihlar T. , Fuller M.D. , Cherrington J.M. Expression of the catalytic subunit (UL54) and the accessory protein (UL44) of human cytomegalovirus DNA polymerase in a coupled in vitro transcription/translation system. Protein Expr Purif 1997; 11: 209–218.

Shi R. , Azzi A. , Gilbert C. , Boivin G. , Lin S.X. Three-dimensional modeling of cytomegalovirus DNA polymerase and preliminary analysis of drug resistance. Proteins 2006; 64: 301–307.

Liu S. , Knafels J.D. , Chang J.S. Crystal structure of the herpes simplex virus 1 DNA polymerase. J Biol Chem 2006; 281: 18193–18200.

Parthiban V. , Gromiha M.M. , Schomburg D. CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res 2006; 34: W239–W242.

Eriksson B. , Oberg B. , Wahren B. Pyrophosphate analogues as inhibitors of DNA polymerases of cytomegalovirus, herpes simplex virus and cellular origin. Biochim Biophys Acta 1982; 696: 115–123.

Baldanti F. , Underwood M.R. , Stanat S.C. Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS. J Virol 1996; 70: 1390–1395.

Springer K.L. , Chou S. , Li S. How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol 2005; 43: 208–213.

Ducancelle A. , Champier G. , Alain S. A novel mutation in the UL54 gene of human cytomegalovirus isolates that confers resistance to foscarnet. Antivir Ther 2006; 11: 537–540.

Franklin M.C. , Wang J. , Steitz T.A. Structure of the replicating complex of a pol alpha family DNA polymerase. Cell 2001; 105: 657–667.

Bestman-Smith J. , Boivin G. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J Virol 2003; 77: 7820–7829.

Andrei G. , Fiten P. , Froeyen M. DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions. Antivir Ther 2007; 12: 719–732.